Log in to search using one of your social media accounts:


Incidence of Diabetic Retinopathy Between T1DM and T2DM Incidence of Diabetic Retinopathy Between T1DM and T2DM

A new study found a greater incidence of diabetic retinopathy among type 1 diabetics than in those with type 2, highlighting the importance of regular screening in these patients.The British Journal of Ophthalmology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news

Related Links:

Transcription factor 19 (TCF19) has been reported as a type 1 diabetes–associated locus involved in maintenance of pancreatic β cells through a fine-tuned regulation of cell proliferation and apoptosis. TCF19 also exhibits genomic association with type 2 diabetes, although the precise molecular mechanism remains unknown. It harbors both a plant homeodomain and a forkhead-associated domain implicated in epigenetic recognition and gene regulation, a phenomenon that has remained unexplored. Here, we show that TCF19 selectively interacts with histone 3 lysine 4 trimethylation through its plant homeodomain finger. Kn...
Source: Journal of Biological Chemistry - Category: Chemistry Authors: Tags: Gene Regulation Source Type: research
Source: CDC Morbidity and Mortality Weekly Report - Category: American Health Source Type: news
Conclusions The pancreatic exocrine SP is a potential reservoir of adult stem/progenitor cells, consistent with previous evidence that such cells are duct-derived and express CD133.
Source: Pancreas - Category: Gastroenterology Tags: Original Articles Source Type: research
Authors: Briski KP, Alhamami HN, Alshamrani A, Mandal SK, Shakya M, Ibrahim MHH Abstract Vital nerve cell functions, including maintenance of transmembrane voltage and information transfer, occur at high energy expense. Inadequate provision of the obligate metabolic fuel glucose exposes neurons to risk of dysfunction or injury. Clinical hypoglycemia rarely occurs in nondiabetic individuals but is an unfortunate regular occurrence in patients with type 1 or advanced insulin-treated type 2 diabetes mellitus. Requisite strict glycemic control, involving treatment with insulin, sulfonylureas, or glinides, can cause fre...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Authors: Mauvais-Jarvis F Abstract Some aspects of glucose homeostasis and energy balance are regulated differently in males and females. This review discusses the most fundamental gender differences in diabetes and obesity, including the prevalence of impaired fasting glucose and impaired glucose tolerance, the prevalence and incidence of type 2 and type 1 diabetes, as well as the prevalence of metabolic syndrome and obesity. These gender-specific differences in glucose homeostasis and energy balance represent a source of factors that should be studied to develop gender-based therapeutic avenues for diabetes. ...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
The FDA today approved Admelog (insulin lispro injection), a short-acting insulin indicated to improve control in blood sugar levels in adults and pediatric patients 3 years and older with type 1 diabetes mellitus and adults with type 2 diabetes mellitus. Admelog is the first short-acting insulin approved as a “follow-on” product.
Source: Food and Drug Administration - Category: American Health Source Type: news
Abstract To investigate the spectrum of diseases seen in diabetes mellitus in a forensic context, all autopsy reports of diabetic individuals who presented to Forensic Science, South Australia (FSSA), over a 5-year period from 2005 to 2009 were studied. The leading cause of death was cardiovascular disease (55.0%), followed by unnatural deaths (15.4%) and infections (9.4%). In type 1 diabetics, principal causes of death included cardiovascular disease (44.7%), acute metabolic complications (18.7%), unnatural deaths (17.9%), and infections (8.9%). However, frequencies of these diseases differed in type 2 diabetics,...
Source: Journal of Forensic Sciences - Category: Forensic Medicine Authors: Tags: J Forensic Sci Source Type: research
Authors: Rendell MS Abstract INTRODUCTION: Sotagliflozin is the first dual SGLT1/SGLT2 inhibitor developed for use in diabetes. Sotagliflozin blocks SGLT2 in the kidneys and SGLT1 in the intestines resulting in reduced early phase glucose absorption and increased blood levels of GLP-1 and PYY. Urinary glucose excretion is lower than with other agents as a result of decreased glucose absorption. The primary development effort to date has been in Type 1 diabetes. AREAS COVERED: The published information on sotagliflozin is reviewed, along with the recent results of several pivotal Type 1 diabetes trials. EXPE...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
Conclusions: Type 1 and type 2 diabetes have excess long-term mortality. In the nondiabetic and type 2 diabetic patients, a reduction in mortality has been noted in recent years, but has not been observed in type 1 diabetic patients.Cardiology 2018;139:43-52
Source: Cardiology - Category: Cardiology Source Type: research
AbstractAims/hypothesisThe aim of this study was to determine whether random non-fasting C-peptide (rCP) measurement can be used to assess hypoglycaemia risk in insulin-treated type 2 diabetes.MethodsWe compared continuous glucose monitoring-assessed SD of blood glucose and hypoglycaemia duration in 17 patients with insulin-treated type 2 diabetes and severe insulin deficiency (rCP    600 pmol/l). We then assessed the relationship between rCP and questionnaire-based measures of hypoglycaemia in 256 patients with insulin-treated type 2 diabetes and a comparison group of 209 individuals with type 1 diabetes.Re...
Source: Diabetologia - Category: Endocrinology Source Type: research
More News: Diabetes | Diabetes Type 1 | Diabetes Type 2 | Endocrinology | Health | Opthalmology | Study | UK Health